Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.
AffiliationNightingale and Genesis Breast Cancer Prevention Centre, University Hospital of South Manchester, Manchester M23 9LT, UK
MetadataShow full item record
AbstractBackground:Randomised trials of tamoxifen versus placebo indicate that tamoxifen reduces breast cancer risk by approximately 33%, yet uptake is low. Approximately 10% of women in our clinic entered the IBIS-I prevention trial. We assess the uptake of tamoxifen in a consecutive series of premenopausal women not in a trial and explore the reasons for uptake through interviews.Methods:All eligible women between 33 and 46 years at 17% lifetime risk of breast cancer and undergoing annual mammography in our service were invited to take a 5-year course of tamoxifen. Reasons for accepting (n=15) or declining (n=15) were explored using semi-structured interviews.Results:Of 1279 eligible women, 136 (10.6%) decided to take tamoxifen. Women >40 years (74 out of 553 (13.4%)) and those at higher non-BRCA-associated risk were more likely to accept tamoxifen (129 out of 1109 (11.6%)). Interviews highlighted four themes surrounding decision making: perceived impact of side effects, the impact of others' experience on beliefs about tamoxifen, tamoxifen as a 'cancer drug', and daily reminder of cancer risk.Conclusions:Tamoxifen uptake was similar to previously ascertained uptake in a randomised controlled trial (IBIS-I). Concerns were similar in women who did or did not accept tamoxifen. Decision making appeared to be embedded in the experience of significant others.British Journal of Cancer advance online publication, 4 March 2014; doi:10.1038/bjc.2014.109 www.bjcancer.com.
CitationUptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. 2014: Br J Cancer
JournalBritish Journal of Cancer
- Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
- Authors: Jankowitz RC, McGuire KP, Davidson NE
- Issue date: 2013 Aug
- Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
- Authors: Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, Formelli F, Lien EA, Pelosi G, Johnson KA, Bonanni B
- Issue date: 2009 Aug 10
- Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.
- Authors: Taylor R, Taguchi K
- Issue date: 2005 May-Jun
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
- Authors: Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J, IBIS-II investigators.
- Issue date: 2016 Feb 27
- Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
- Authors: Alkner S, Bendahl PO, Fernö M, Nordenskjöld B, Rydén L, South Swedish and South-East Swedish Breast Cancer Groups.
- Issue date: 2009 Sep